Cargando…

Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways

BACKGROUND: Many clinical studies have shown a correlation between proton pump inhibitors (PPIs) and osteoporosis or fractures. The purpose of this study was to establish a murine model of chronic oral PPI administration to verify whether PPIs caused bone metabolic impairment and investigate the rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ziping, Liu, Yangjie, Ma, Mengyuan, Sun, Shiyu, Ma, Zengqing, Wang, Yu, Yu, Liyuan, Qian, Xuping, Sun, Luning, Zhang, Xuehui, Liu, Yun, Wang, Yongqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858482/
https://www.ncbi.nlm.nih.gov/pubmed/35183103
http://dx.doi.org/10.1186/s10020-022-00448-x
_version_ 1784654248965832704
author Cheng, Ziping
Liu, Yangjie
Ma, Mengyuan
Sun, Shiyu
Ma, Zengqing
Wang, Yu
Yu, Liyuan
Qian, Xuping
Sun, Luning
Zhang, Xuehui
Liu, Yun
Wang, Yongqing
author_facet Cheng, Ziping
Liu, Yangjie
Ma, Mengyuan
Sun, Shiyu
Ma, Zengqing
Wang, Yu
Yu, Liyuan
Qian, Xuping
Sun, Luning
Zhang, Xuehui
Liu, Yun
Wang, Yongqing
author_sort Cheng, Ziping
collection PubMed
description BACKGROUND: Many clinical studies have shown a correlation between proton pump inhibitors (PPIs) and osteoporosis or fractures. The purpose of this study was to establish a murine model of chronic oral PPI administration to verify whether PPIs caused bone metabolic impairment and investigate the relevant molecular mechanism underlying the effects of PPIs on MC3T3-E1 murine osteoblasts. METHODS: A lansoprazole-induced bone loss model was used to investigate the damaging effects of PPIs. In vivo, immunohistochemistry, Hematoxylin–Eosin (HE) staining, micro-CT analysis, and blood biochemical analyses were used to evaluate the effect of lansoprazole on bone injury in mice. In vitro, the effects of lansoprazole and related signaling pathways in MC3T3-E1 cells were investigated by CCK-8 assays, EdU assays, flow cytometry, laser confocal microscopy, patch clamping, reverse transcription-quantitative polymerase chain reaction and Western blotting. RESULTS: After 6 months of lansoprazole gavage in ICR mice, the micro-CT results showed that compared with that in the vehicle group, the bone mineral density (BMD) in the high-dose group was significantly decreased (P < 0.05), and the bone microarchitecture gradually degraded. Biochemical analysis of bone serum showed that blood calcium and phosphorus were both decreased (P < 0.01). We found that long-term administration of lansoprazole impaired skeletal function in mice. In vitro, we found that lansoprazole (LPZ) could cause calcium overload in MC3T3-E1 cells leading to apoptosis, and 2-APB, an inhibitor of IP3R calcium release channel and SOCE pathway, effectively blocked increase in calcium caused by LPZ, thus protecting cell viability. CONCLUSIONS: Longterm administration of LPZ induced osteoporotic symptoms in mice, and LPZ triggered calcium increases in osteoblasts in a concentration-dependent manner. Intracellular calcium ([Ca(2+)](i)) persisted at a high concentration, thereby causing endoplasmic reticulum stress (ERS) and inducing osteoblast apoptosis.
format Online
Article
Text
id pubmed-8858482
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88584822022-02-22 Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways Cheng, Ziping Liu, Yangjie Ma, Mengyuan Sun, Shiyu Ma, Zengqing Wang, Yu Yu, Liyuan Qian, Xuping Sun, Luning Zhang, Xuehui Liu, Yun Wang, Yongqing Mol Med Research Article BACKGROUND: Many clinical studies have shown a correlation between proton pump inhibitors (PPIs) and osteoporosis or fractures. The purpose of this study was to establish a murine model of chronic oral PPI administration to verify whether PPIs caused bone metabolic impairment and investigate the relevant molecular mechanism underlying the effects of PPIs on MC3T3-E1 murine osteoblasts. METHODS: A lansoprazole-induced bone loss model was used to investigate the damaging effects of PPIs. In vivo, immunohistochemistry, Hematoxylin–Eosin (HE) staining, micro-CT analysis, and blood biochemical analyses were used to evaluate the effect of lansoprazole on bone injury in mice. In vitro, the effects of lansoprazole and related signaling pathways in MC3T3-E1 cells were investigated by CCK-8 assays, EdU assays, flow cytometry, laser confocal microscopy, patch clamping, reverse transcription-quantitative polymerase chain reaction and Western blotting. RESULTS: After 6 months of lansoprazole gavage in ICR mice, the micro-CT results showed that compared with that in the vehicle group, the bone mineral density (BMD) in the high-dose group was significantly decreased (P < 0.05), and the bone microarchitecture gradually degraded. Biochemical analysis of bone serum showed that blood calcium and phosphorus were both decreased (P < 0.01). We found that long-term administration of lansoprazole impaired skeletal function in mice. In vitro, we found that lansoprazole (LPZ) could cause calcium overload in MC3T3-E1 cells leading to apoptosis, and 2-APB, an inhibitor of IP3R calcium release channel and SOCE pathway, effectively blocked increase in calcium caused by LPZ, thus protecting cell viability. CONCLUSIONS: Longterm administration of LPZ induced osteoporotic symptoms in mice, and LPZ triggered calcium increases in osteoblasts in a concentration-dependent manner. Intracellular calcium ([Ca(2+)](i)) persisted at a high concentration, thereby causing endoplasmic reticulum stress (ERS) and inducing osteoblast apoptosis. BioMed Central 2022-02-19 /pmc/articles/PMC8858482/ /pubmed/35183103 http://dx.doi.org/10.1186/s10020-022-00448-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Cheng, Ziping
Liu, Yangjie
Ma, Mengyuan
Sun, Shiyu
Ma, Zengqing
Wang, Yu
Yu, Liyuan
Qian, Xuping
Sun, Luning
Zhang, Xuehui
Liu, Yun
Wang, Yongqing
Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways
title Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways
title_full Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways
title_fullStr Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways
title_full_unstemmed Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways
title_short Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways
title_sort lansoprazole-induced osteoporosis via the ip3r- and soce-mediated calcium signaling pathways
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858482/
https://www.ncbi.nlm.nih.gov/pubmed/35183103
http://dx.doi.org/10.1186/s10020-022-00448-x
work_keys_str_mv AT chengziping lansoprazoleinducedosteoporosisviatheip3randsocemediatedcalciumsignalingpathways
AT liuyangjie lansoprazoleinducedosteoporosisviatheip3randsocemediatedcalciumsignalingpathways
AT mamengyuan lansoprazoleinducedosteoporosisviatheip3randsocemediatedcalciumsignalingpathways
AT sunshiyu lansoprazoleinducedosteoporosisviatheip3randsocemediatedcalciumsignalingpathways
AT mazengqing lansoprazoleinducedosteoporosisviatheip3randsocemediatedcalciumsignalingpathways
AT wangyu lansoprazoleinducedosteoporosisviatheip3randsocemediatedcalciumsignalingpathways
AT yuliyuan lansoprazoleinducedosteoporosisviatheip3randsocemediatedcalciumsignalingpathways
AT qianxuping lansoprazoleinducedosteoporosisviatheip3randsocemediatedcalciumsignalingpathways
AT sunluning lansoprazoleinducedosteoporosisviatheip3randsocemediatedcalciumsignalingpathways
AT zhangxuehui lansoprazoleinducedosteoporosisviatheip3randsocemediatedcalciumsignalingpathways
AT liuyun lansoprazoleinducedosteoporosisviatheip3randsocemediatedcalciumsignalingpathways
AT wangyongqing lansoprazoleinducedosteoporosisviatheip3randsocemediatedcalciumsignalingpathways